The model compartmentalizes cannabis into two main constituents: THC, exerting risk for raised schizophrenia rates in the context of neurochemical disturbance, genetic load (COMT, AKT1), and population risk exposure, and CBD, which is related to benefits in the schizophrenia spectrum, which should be corroborated in targeted clinical analyses. The gene discussed is AKT1; the disease is schizophrenia.